T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
Aemetis
AMTX
$129M
| $99K | ﹤0.01% |
32,735
+22,635
| +224% | +$86.3K |
|
2752
eHealth
EHTH
$24.2M
| $99K | ﹤0.01% |
21,723
-7,571
| -26% | -$38.1K |
|
2753
Larimar Therapeutics
LRMR
$320M
| $98K | ﹤0.01% |
+13,460
| New | +$103K |
|
2754
Vuzix
VUZI
$248M
| $98K | ﹤0.01% |
71,900
-14,480
| -17% | -$20K |
|
2755
Vanda Pharmaceuticals
VNDA
$305M
| $97K | ﹤0.01% |
17,030
+1,206
| +8% | +$6.23K |
|
2756
ClearPoint Neuro
CLPT
$452M
| $96K | ﹤0.01% |
17,700
-7,167
| -29% | -$41.5K |
|
2757
Citizens
CIA
$182M
| $95K | ﹤0.01% |
34,900
| – | – |
|
2758
Planet Labs
PL
$6.34B
| $95K | ﹤0.01% |
50,678
| – | – |
|
2759
Definitive Healthcare
DH
$101M
| $94K | ﹤0.01% |
17,076
+3,685
| +28% | +$23.2K |
|
2760
Rigel Pharmaceuticals
RIGL
$900M
| $93K | ﹤0.01% |
11,304
-1
| -0% | -$10 |
|
2761
SES AI
SES
$198M
| $93K | ﹤0.01% |
74,278
| – | – |
|
2762
Beam Global
BEEM
$26.9M
| $91K | ﹤0.01% |
19,600
| – | – |
|
|
IAUX
2763
i-80 Gold Corp
IAUX
$1.51B
| $90K | ﹤0.01% |
83,064
+25,051
| +43% | +$29.4K |
|
2764
Target Hospitality
TH
$2.02B
| $90K | ﹤0.01% |
+10,281
| New | +$107K |
|
2765
Veru
VERU
$43.3M
| $90K | ﹤0.01% |
10,611
+4,281
| +68% | +$49.5K |
|
|
TWKS
2766
DELISTED
Thoughtworks Holding, Inc. Common Stock
TWKS
| $89K | ﹤0.01% |
31,083
+5,901
| +23% | +$15.8K |
|
2767
Erasca
ERAS
$4.98B
| $86K | ﹤0.01% |
36,145
+11,461
| +46% | +$24.7K |
|
|
ACCD
2768
DELISTED
Accolade Inc
ACCD
| $85K | ﹤0.01% |
23,691
+4,151
| +21% | +$31.4K |
|
2769
Amplify Energy
AMPY
$177M
| $84K | ﹤0.01% |
12,277
+2,206
| +22% | +$14.5K |
|
2770
Karyopharm Therapeutics
KPTI
$36.7M
| $84K | ﹤0.01% |
6,473
+134
| +2% | +$2.22K |
|
|
KYNB
2771
Kyntra Bio
KYNB
$28.1M
| $83K | ﹤0.01% |
3,716
-974
| -21% | -$30.1K |
|
|
SGMO
2772
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $83K | ﹤0.01% |
236,100
-42,604
| -15% | -$23K |
|
2773
Mammoth Energy Services
TUSK
$143M
| $81K | ﹤0.01% |
24,431
+696
| +3% | +$2.39K |
|
|
AIRJW
2774
AirJoule Technologies Warrant
AIRJW
$56.3M
| $81K | ﹤0.01% |
56,154
| – | – |
|
|
FARM
2775
DELISTED
Farmer Brothers
FARM
| $80K | ﹤0.01% |
29,600
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.